Incyte Stock Performance
| INCY Stock | USD 69.91 0.07 0.10% |
Incyte has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.19, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Incyte will likely underperform. Incyte right now retains a risk of 2.55%. Please check out Incyte potential upside, and the relationship between the jensen alpha and accumulation distribution , to decide if Incyte will be following its current trending patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Incyte are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Incyte may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Actual Historical Performance (%)
One Day Return 0.1 | Five Day Return 4.51 | Year To Date Return 6.81 | Ten Year Return (5.39) | All Time Return 3.6 K |
Last Split Factor 2:1 | Last Split Date 2000-09-01 |
1 | Disposition of 2136 shares by Sheila Denton of Incyte at 67.63 subject to Rule 16b-3 | 10/11/2024 |
2 | Acquisition by Flannelly Barry P of 2256 shares of Incyte at 68.62 subject to Rule 16b-3 | 11/08/2024 |
3 | Acquisition by Trotta Matteo of 2646 shares of Incyte subject to Rule 16b-3 | 11/22/2024 |
4 | Riassunto Incyte annuncer nuovi dati, inclusa una presentazione orale dellultima ora su tafasitamab nel linfoma follicolare, al congresso annuale 2024 dellASH | 11/26/2024 |
5 | Disposition of 4961 shares by Herve Hoppenot of Incyte at 64.25 subject to Rule 16b-3 | 11/29/2024 |
6 | Erste Asset Management GmbH Takes 3.37 Million Position in Incyte Co. | 12/03/2024 |
7 | Disposition of 1510 shares by Flannelly Barry P of Incyte at 72.11 subject to Rule 16b-3 | 12/09/2024 |
8 | Biotech Stock Roundup BIOA Down on Study Update, QURE, CRDF Gain on Study Data More | 12/11/2024 |
9 | Les donnes de dernires minutes dIncyte sur le tafasitamab lASH 2024 dmontrent une survie sensiblement amliore de la survie sans progression chez les patients at... | 12/12/2024 |
10 | Incyte Corp to Present at 43rd Annual J.P. Morgan Healthcare Conference | 12/17/2024 |
11 | MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease | 12/19/2024 |
12 | Insider Selling Incyte Co. Insider Sells 45,051.50 in Stock | 12/20/2024 |
13 | Critical Survey Tenax Therapeutics and Merus | 12/23/2024 |
| Begin Period Cash Flow | 3 B |
Incyte |
Incyte Relative Risk vs. Return Landscape
If you would invest 6,513 in Incyte on September 26, 2024 and sell it today you would earn a total of 478.00 from holding Incyte or generate 7.34% return on investment over 90 days. Incyte is currently generating 0.1441% in daily expected returns and assumes 2.5525% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Incyte, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Incyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Incyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Incyte, and traders can use it to determine the average amount a Incyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0564
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | INCY | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Incyte is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Incyte by adding it to a well-diversified portfolio.
Incyte Fundamentals Growth
Incyte Stock prices reflect investors' perceptions of the future prospects and financial health of Incyte, and Incyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Incyte Stock performance.
| Return On Equity | 0.008 | ||||
| Return On Asset | -0.0012 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 11.72 B | ||||
| Shares Outstanding | 192.65 M | ||||
| Price To Earning | 19.17 X | ||||
| Price To Book | 4.24 X | ||||
| Price To Sales | 3.30 X | ||||
| Revenue | 3.7 B | ||||
| Gross Profit | 1.59 B | ||||
| EBITDA | 919.43 M | ||||
| Net Income | 597.6 M | ||||
| Cash And Equivalents | 2.72 B | ||||
| Cash Per Share | 12.24 X | ||||
| Total Debt | 38.29 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.91 X | ||||
| Book Value Per Share | 16.45 X | ||||
| Cash Flow From Operations | 496.49 M | ||||
| Earnings Per Share | 0.09 X | ||||
| Market Capitalization | 13.47 B | ||||
| Total Asset | 6.78 B | ||||
| Retained Earnings | 160.38 M | ||||
| Working Capital | 3.41 B | ||||
| Current Asset | 842.38 M | ||||
| Current Liabilities | 168.01 M | ||||
About Incyte Performance
Evaluating Incyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Incyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Incyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 90.14 | 150.23 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.12 | 0.19 |
Things to note about Incyte performance evaluation
Checking the ongoing alerts about Incyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Incyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Incyte has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Critical Survey Tenax Therapeutics and Merus |
- Analyzing Incyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Incyte's stock is overvalued or undervalued compared to its peers.
- Examining Incyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Incyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Incyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Incyte's stock. These opinions can provide insight into Incyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.